Abstract:Anastasios Lymperopoulos ^ Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences, Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA ^ ORCID: 0000-0001-9817-6319. Comment on: Lei C, Zhang X, Chen E, et al . Compositional alterations of the gut microbiota in acute myocardial infarction patients with type 2 diabetes mellitus. Ann Transl Med 2023;11:317. Keywords: Diabetes mellitus; free fatty acid receptors; gut microbiota; myocardial infarction (MI); short chain fatty acid metabolites Submitted Jul 06, 2023. Accepted for publication Aug 09, 2023. Published online Sep 05, 2023. doi: 10.21037/atm-23-1741 Heart attack [myocardial infarction (MI)] prevalence is increasing worldwide but very little is known about the roles gut microbiota play in its pathogenesis and epidemiology (1,2). Similarly, the role of gut microbiota alterations in type 2 diabetes mellitus (T2DM), a significant co-morbidity in many patients with MI, is still under intense investigation (3). The recently published study by Lei et al. (4) hypothesized that the gut microbiota composition might differ between acute MI patients with T2DM (AMIDM) and acute MI patients without T2DM (AMINDM), potentially conferring poorer prognosis in AMIDM patients, and it set out to investigate this hypothesis by examining the gut microbiota profiles of patients belonging to these two groups. Using 16S rDNA sequencing to examine the different compositions and functions of the gut microbiota from 15 AMIDM and 15 AMINDM patients, the study found their postulated hypothesis to hold true: gut microbiota compositions do differ between the two groups and also predict their functions (4). Importantly, significant correlations between certain bacterial species and clinical parameters of AMI patients were uncovered, as well (4). Microbial shaping and colonization of the gut begins perinatally and changes in its content are influenced by various factors, including genetic, dietary, and environmental factors (5). Dietary habits, medications, and genetics are all known to precipitate dysbiosis of the gut microbiota, contributing to T2DM pathogenesis (5,6). The differences observed in the study by Lei et al. (4) most likely stemmed from variations in diet and genetic background of the study's patients. Regarding specific findings of the study, Firmicutes and Bacteroidetes were found to be the most prevalent phyla (4). Indeed, alterations in these two phyla have already been strongly associated with cardiovascular and metabolic disease progression in previous studies (7,8). Of note, most of the bacteria species belonging to these two phyla are short chain fatty acid (SCFA)-producing species, i.e., butyrate, propionate, or acetate metabolite-producing microbes, which means that these alterations in the Firmicutes/Bacteroidetes levels or ratios may promote heart disease through SCFA-dependent mechanisms (8). Consistent with other studies suggesting an elevated Firmicutes/Bacteroidetes ratio might accompany various diseases, such as T2DM, obesity, and atherosclerosis/coronary artery disease (9-11), Lei et al. also found an increase in Firmicutes abundance but a decrease in Bacteroidetes levels in AMIDM patients (4). This indicates that a higher Firmicutes/Bacteroidetes ratio might be a feature of acute MI with T2DM, as well. Most bacteria belonging to the Firmicutes are gram-positive and associated with unhealthy lifestyles, such as a high-fat diet (12), energy imbalance (13), and high body mass index (overweight) (14). In contrast, Bacteroidetes consist of gram-negative bacteria, which can be induced by consumption of fiber-rich or carbohydrate-rich diets, and whose population seems to decrease as atherosclerosis progresses (15-17). Of note, several studies investigating specific gut microbial profiles of coronary artery disease patients seem to agree that a common feature of gut microbiota alterations in these patients is an increased Firmicutes/Bacteroidetes ratio, i.e., higher Firmicutes and lower Bacteroidetes species levels (9,18,19). The study by Lei et al. adds patients with AMIDM to the list of heart disease patients presenting this altered gut microbiota signature (4). Whether the presence of T2DM complicating MI in these patients alters this ratio itself to promote inflammation and insulin resistance, or the higher Firmicutes-to-Bacteroidetes ratio is the result of the increased systemic and cardiovascular chronic inflammation and/or the metabolic syndrome caused by the diabetes, remains an open but very important question awaiting answer in future studies. It is also plausible that both possibilities could be in play: the higher Firmicutes/Bacteroidetes ratio could both be involved in the pathogenesis of T2DM-induced cardiovasc -Abstract Truncated-

Gut microbiota dysbiosis in stable coronary artery disease combined with type 2 diabetes mellitus influences cardiovascular prognosis

Gut microbiota dysbiosis in stable coronary artery disease combined type 2 diabetes mellitus influence cardiovascular prognosis

Gut Microbiota and Subclinical Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus

Multiple Bacteria Associated with the More Dysbiotic Genitourinary Microbiomes in Patients with Type 2 Diabetes Mellitus

Multi-omics mechanical analysis of gut microbiota, carboxylic acids, and cardiac gene expression interaction triggering diabetic cardiomyopathy

Gut Microbiota and Metabolic Alterations Associated with Heart Failure and Coronary Artery Disease

The Gut Microbiome in Atherosclerotic Cardiovascular Disease.

Altered Gut Microbiota as a Potential Risk Factor for Coronary Artery Disease in Diabetes: A Two-Sample Bi-Directional Mendelian Randomization Study

Characterization of gut microbiota in adults with coronary atherosclerosis

Gut macrobiotic and its metabolic pathways modulate cardiovascular disease

Metagenomic and Targeted Metabolomic Analyses Reveal Distinct Phenotypes of the Gut Microbiota in Patients with Colorectal Cancer and Type 2 Diabetes Mellitus

Gut microbiota: A new therapeutic target for diabetic cardiomyopathy

Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship

Gut Microbiota Community Shift with Severity of Coronary Artery Disease

Metagenomic analysis of the gut microbiome in atherosclerosis patients identify cross-cohort microbial signatures and potential therapeutic target

Compositional alterations of the gut microbiota in acute myocardial infarction patients with type 2 diabetes mellitus

The role and mechanisms of gut microbiota in diabetic nephropathy, diabetic retinopathy and cardiovascular diseases

Unlocking Cardioprotective Potential of Gut Microbiome: Exploring Therapeutic Strategies

Gut microbiota alterations in acute myocardial infarction: (diabetic) context is everything

Population study of the gut microbiome: associations with diet, lifestyle, and cardiometabolic disease

Abstract MP23: Circulating Gut Microbiota-Related Metabolites and Risk of Coronary Heart Disease: A Prospective, Multiethnic, Metabolomic Study